EP2953597A1 - Pansement transparent pour plaie ou affection cutanée et système de traitement - Google Patents

Pansement transparent pour plaie ou affection cutanée et système de traitement

Info

Publication number
EP2953597A1
EP2953597A1 EP14748552.8A EP14748552A EP2953597A1 EP 2953597 A1 EP2953597 A1 EP 2953597A1 EP 14748552 A EP14748552 A EP 14748552A EP 2953597 A1 EP2953597 A1 EP 2953597A1
Authority
EP
European Patent Office
Prior art keywords
wound
adhesive
skin
covering portion
skin condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14748552.8A
Other languages
German (de)
English (en)
Other versions
EP2953597B1 (fr
EP2953597A4 (fr
Inventor
Alfred J. Lagreca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAGRECA, ALFRED J.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2953597A1 publication Critical patent/EP2953597A1/fr
Publication of EP2953597A4 publication Critical patent/EP2953597A4/fr
Application granted granted Critical
Publication of EP2953597B1 publication Critical patent/EP2953597B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
    • A61F13/025—Adhesive bandages or dressings characterised by the skin-adhering layer having a special distribution arrangement of the adhesive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
    • A61F13/0233—Adhesive bandages or dressings wound covering film layers without a fluid retention layer characterised by the oclusive layer skin contacting layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
    • A61F13/0253—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the adhesive material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0259—Adhesive bandages or dressings characterised by the release liner covering the skin adhering layer
    • A61F13/0266—Adhesive bandages or dressings characterised by the release liner covering the skin adhering layer especially adapted for wound covering/occlusive dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00553—Plasters form or structure with detachable parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/0057—Plasters form or structure with openable cover
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00846—Plasters with transparent or translucent part

Definitions

  • This disclosure relates to a dressing for wounds or skin conditions.
  • Wound dressings can need to be removed so that the caregiver can check the condition of the wound. The dressing then needs to be replaced. Since the dressings are adhered to the skin, such repeated removal of dressings can damage the skin, cause pain, and lead to infections and other side effects.
  • a purpose of the disclosure is to reduce the number of adverse events caused by the time required for nurses, doctors and patients to remove taped dressings from wounds for evaluation or for changing, as well as to reduce the negative factors related to the removing of the tape.
  • the removal of tape, over the time required for wounds to heal, can cause scaring, infections and dermatitis. Further, the necessary repeated removal is very painful.
  • the 24/7 observation of incisions or wounds without exudates allowed by the transparent cover member can significantly reduce the severity of infections. Also, this wound observation takes place while the wound remains sterile under the transparent cover member. There is thus no additional risk of acquiring a hospital acquired infection (HAI) as can happen when a dressing is lifted or removed so that the wound can be inspected.
  • HAI hospital acquired infection
  • HAIs air-borne pathogens that infect a wound during a dressing change.
  • the present see-through dressing system helps to protect the patient from HAIs, as in many cases because the wound can be inspected under aseptic conditions, the dressing can remain on during the entire hospital stay. Since there are fewer deleterious pathogens in the home environment, changing the dressing at home may reduce the risk of infections.
  • the disclosure has at least the following benefits:
  • a reclosable wound or skin condition dressing and treatment system comprising a base portion having a circumference and lower and upper sides, the lower side carrying a first adhesive that is constructed and arranged to adhere to the skin, the upper side defining an adhesive release surface, and a covering portion having a second adhesive on its lower side that releasably engages with the release surface of the base portion, and an upper side comprising a semi-permeable layer, the covering portion overlying at least part of and engaging with the upper side of the base portion, wherein the semi-permeable layer of the covering portion fully covers the open area of the base portion, so as to cover a wound or skin condition located in the open area.
  • the semi-permeable layer of the covering portion is clear or translucent so that a caregiver can see through it to observe the skin, wound, skin condition or dressing below.
  • the first adhesive may comprise a hydrocolloid adhesive.
  • the second adhesive may comprise a pressure-sensitive tape.
  • the base portion may circumscribe a wound or skin condition.
  • the covering portion may overly essentially all of the base portion.
  • the covering portion may define a pull tab adapted to be gripped by a user to assist in separating the covering portion from the base portion.
  • the system may further comprise a removable protective cover over the first adhesive on the lower side of the base portion.
  • a reclosable wound or skin condition dressing and treatment system comprising a covering portion having a lower side that defines an annular adhesive and an upper side comprising a clear or translucent semi-permeable layer, the covering portion spanning the opening of the annulus such that it fully covers the open area of the annulus, to cover a wound or skin condition located in the open area while keeping the wound or skin condition visible through the covering portion.
  • the adhesive may comprise a hydrocolloid adhesive.
  • the covering portion may circumscribe a wound or skin condition.
  • the covering portion may define a pull tab adapted to be gripped by a user to assist in separating the covering portion from the skin.
  • the system may further comprise a removable protective cover over the adhesive.
  • Figure 1 is a cross-sectional view of a two-piece wound dressing system in place surrounding a wound or skin condition.
  • Figure 2 is a cross-sectional view of a one-piece wound dressing system in place surrounding a wound or skin condition.
  • Figure 3 is a top view of the one-piece wound dressing system in place surrounding a wound or skin condition, shown in figure 2.
  • This invention may be accomplished in a disposable or reclosable wound or skin condition dressing and treatment system.
  • One non-limiting example of the inventive wound or skin condition dressing and treatment system 10, figure 1 has two separable components: a base member 20 that is adhered to skin surface S, and a cover or top member 30 that is removably adhered to the top of base member 20.
  • a bandage, dressing pad or treatment pad itself can be but does not need to be held in place against the skin.
  • the base member 20 is an annulus or other shape that defines or encompasses an open area.
  • the base member is semi-permanently adhered to the skin, with the wound or skin condition "W" being treated located within the open area such that the base surrounds the wound or skin condition, preferably without touching it.
  • Member 20 can comprise an annulus 22 of a hydrocolloid with an adhesive on the lower side that is covered with a removable protective covering (not shown) that is removed just before use.
  • Top layer 24 of base member 20 can be a polyethylene film (or another plastic from which an adhesive can be released) that is the same size and shape as annulus 22 and is adhered to the top of annulus 22.
  • the base member provides the function of a means to removably couple the top member to the skin, while the top member may be spaced from the skin so as not to disturb the wound.
  • the adhesion of the base member to the skin may be accomplished with any known adhesive that is compatible with skin.
  • the adhesive may be that used on NEXCARE absolute waterproof first aid tape by the 3M Company, or a hydrocolloid adhesive such as that disclosed in US Patent 4,952,618, for example, or foam tape from 3M.
  • These adhesives may remain in contact with the skin for five to ten days under normal use, including movement and exposure to water, without loosening and without substantial negative impact to the skin.
  • tape is not used and the base member remains on the skin for multiple days. This obviates the need for frequent removal of tape from the skin that leads to so many problems in the current wound-care regimen.
  • the base can have a desired, preferably annular shape, such as a circular, oval or rectangular annulus, for example.
  • the adhesive on the lower side of the base is used to secure the base to the person's skin, surrounding the wound or area of the skin requiring covering or treatment.
  • Adhesives that can be used to couple the base to the skin can also include hydrocoUoid material such as 3M #9943 or #9944, or Duoderni by Convatec of Skellman, NJ, or an adhesive hydrogel such as available from Scapa North America in Windsor, CT.
  • the adhesive would normally be covered with a removable protective layer as is commonly used to protective the sticky side of an adhesive tape, label or sticker.
  • the base is preferably sterile, and can be made with anti-bacterial material.
  • Top member 30 can be of the same size and perimeter shape as the base member, except that it is not annular. Accordingly, member 30 covers base member 20, and also spans the opening defined by the base member, to enclose the volume "V" in which wound or skin condition W is located, and also enclose a dressing or treatment pad should such be used.
  • Top member 30 is preferably constructed with an annulus 32 of polyurethane medical grade adhesive tape that overlies some or all of base annulus 22.
  • Top member 30 also includes a semi-permeable sheet or membrane 34. Sheet 34 may be but need not be a polyurethane membrane, one example of which is 3M #9833. Sheet 34 may be secured to annulus 32. Sheet 34 spans the annular opening of base 20. Sheet 34 is preferably adhesive-free so that it does not adhere to the wound or any dressing that touches sheet 34.
  • Top member 30 is sterile and can be made of anti-bacterial material.
  • Sheet 34 is preferably translucent or clear. Sheet 34 may also be hydrophobic. If sheet 34 is clear or translucent, the pad or the underlying skin region can be inspected without separating the top member from the bottom member.
  • the subject system is a very low-profile wound covering that can stay in place for many days, thus decreasing the need to pull tape off of the skin in order to view a wound, or change a bandage or treatment pad.
  • the result is less patient pain and suffering, and decreased costs associated with treating infections caused by repeated tape removal, which is prevalent in chronic-care situations in which a dressing may need to be changed multiple times per day, for a week or more.
  • This also decreases medical costs by changing dressings only when necessary, decreased waste and decreased labor costs associated with removing tapes and their residue.
  • Increasing nursing and medical availability caused by this invention will decrease adverse events causing complications and sometimes death.
  • the invention allows for the continuous observation of an incision or wound without exudates. This allows infections, swelling, redness or bursting and other disorders to be identified immediately, which can lead to a significant reduction of the severity of infections and the associated costs.
  • the subject system contemplates a variety of means for adhesively coupling the base member to the skin of a person or animal, a variety of means for removably coupling the top member to the base member, and a variety of wound and skin condition treatment modalities held in place by the base and top members.
  • the base can be coupled to the skin with any adhesive that accomplishes sufficient adhesion along with the benefits of less skin irritation or damage.
  • adhesive silicone gels such as those manufactured and used by Scapa, Windsor, CT.
  • the inventive dressing can be removably coupled to the skin by an elastic compression wrap bandage overlaying the inventive dressing (such as an Ace bandage from BD, Franklin Lakes, NJ) and wrapped around a portion of the body such as a limb or the torso.
  • the top can be coupled to the base by an adhesive on the bottom side of the top member that is sufficient to hold the top on the base but allows the top to be released from the base and removed.
  • the top can then be placed back on the base at least once if desired, and preferably multiple times, over the up to 5-7 day typical useful life of the inventive device.
  • an adhesive that may be useful for this purpose is a medical grade pressure sensitive tape adhesive such as 3M #1510 on one part (e.g., on the bottom surface of the top member) and an adhesive-releasing plastic surface (e.g., a polyethylene film) on the other part (e.g., making up the top surface of the lower annulus).
  • the pad can carry or comprise or be entirely made from certain known materials that have known medical effects.
  • Foam composites such as Mepilex Soft Silicon by MoLnlycke of Denmark. These products typically serve more than purpose, for example a combination which maintains moisture in the wound site, is a barrier to bacteria, and absorbs excess exudates.
  • Alginates such as Algicell Calcium Alginate by Derma Sciences of Princeton,
  • Silver alginate such as Maxsorb Extra by Medline Industries of Mundelsein, IL.
  • the silver reduces infections from a wide range of microorganisms.
  • Antimicrobial such as Anticoat 7 by Smith and Nephew of London, England. This can be an effective barrier to bacterial penetration that may reduce infections in partial or full thickness wounds.
  • Transparent dressings such as Tegaderm #1628 by 3M allow the wound to be viewed at all times but have the disadvantage of difficulty in removal from the skin and wound.
  • the invention significantly reduces the damage of removal but allows for continued viewing of the wound or skin condition or the like.
  • Hydrocolloids such as Dermatell by Gentell, Inc of Skellman, NJ. These support a moist healing environment and autolytic debridement and non traumatic dressing removal. Hydrogels such as Ameriderm wound gel dressing by Ameriderm Labs Ltd. of Patterson, NJ. The gel's high glycerin content facilitates the natural wound healing process.
  • Silver such as Silverlon by Argentum Medical LLC of Willowbrook, Illinois reduces infections by resisting and eliminating most microorganisms.
  • the invention contemplates other materials, medications and the like, to accomplish any desired or custom treatment of a condition such as skin irritation caused by pressure prior to the wound developing, or a surface wound.
  • the invention speeds and eases wound and skin care and treatment in situations in which the skin needs to be covered.
  • the invention also decreases incidence of tape removal-related infections. The invention thus can reduce the costs associated with wound and skin care.
  • the disclosure also contemplates a single layer dressing 10a, figures 2 and 3, which is essentially top member 30 from figure 1.
  • Adhesive annulus 32a carries transparent sheet 34a, which spans the open area of the annulus. Annulus 32a can be placed directly on the skin. The result is a clear window through which the wound, or any dressing or the like held in place over the wound, can be continuously viewed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un pansement refermable pour plaie ou affection cutanée et un système de traitement (10). Le système (10) a une partie de base (20) qui a une circonférence et des côtés inférieur (22) et supérieur (24), le côté inférieur (22) portant un premier adhésif qui est construit et agencé pour coller à la peau (S), et le côté supérieur (24) définissant une surface anti-adhésive. Une partie de couverture (30) possède un second adhésif sur son côté inférieur (32) qui se met en prise libérable avec la surface anti-adhésive (24) sur la partie de base (20), et un côté supérieur (34) qui est une couche semi-perméable configurée pour couvrir une plaie ou une affection cutanée (W) se trouvant dans la zone ouverte (V) de la partie de base (20). La couche semi-perméable (34) de la partie de couverture (30) est transparente ou translucide pour qu'un personnel de soin puisse voir à travers et observer la peau, la plaie, l'affection cutanée (W) ou le pansement en dessous.
EP14748552.8A 2013-02-07 2014-02-07 Pansement transparent pour plaie ou affection cutanée et système de traitement Active EP2953597B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761992P 2013-02-07 2013-02-07
PCT/US2014/015282 WO2014124242A1 (fr) 2013-02-07 2014-02-07 Pansement transparent pour plaie ou affection cutanée et système de traitement

Publications (3)

Publication Number Publication Date
EP2953597A1 true EP2953597A1 (fr) 2015-12-16
EP2953597A4 EP2953597A4 (fr) 2016-07-20
EP2953597B1 EP2953597B1 (fr) 2020-03-18

Family

ID=51300151

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14748552.8A Active EP2953597B1 (fr) 2013-02-07 2014-02-07 Pansement transparent pour plaie ou affection cutanée et système de traitement

Country Status (3)

Country Link
US (1) US20160374863A1 (fr)
EP (1) EP2953597B1 (fr)
WO (1) WO2014124242A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220015951A1 (en) * 2020-07-19 2022-01-20 BandGrip, Inc. Bandage with replaceable treatment member

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264218A (en) 1989-10-25 1993-11-23 C. R. Bard, Inc. Modifiable, semi-permeable, wound dressing
US5060642A (en) * 1990-01-05 1991-10-29 Gilman Thomas H Wound dressing with air permeable bacteria impermeable reservoir
EP0745366A3 (fr) * 1992-06-19 1996-12-11 AUGUSTINE, Scott D. Couverture de plaie
US5702356A (en) * 1993-12-23 1997-12-30 Hathman; Johnnie L. Disposable wound dressing permitting non-invasive examination
US7622629B2 (en) * 2005-12-15 2009-11-24 Aalnex, Inc. Wound shield for exudate management
US7816577B2 (en) * 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
US20090287133A1 (en) * 2006-06-06 2009-11-19 Lagreca Sr Alfred J Disposable or Reclosable Wound or Skin Condition Dressing and Treatment System
US7576257B2 (en) * 2006-06-06 2009-08-18 Lagreca Sr Alfred J Reclosable wound dressing system
WO2010005910A2 (fr) * 2008-07-08 2010-01-14 Monarch Labs Llc Pansements et procédés utilisables dans le cadre d'un traitement de débridement par des asticots
EP2506815B1 (fr) * 2009-12-03 2019-07-24 Pharmaplast SAE Pansement, et procédé et chaîne de production pour produire le pansement
EP3520830B1 (fr) * 2009-12-22 2023-10-18 Smith & Nephew, Inc. Appareils pour le traitement de plaies par pression négative

Also Published As

Publication number Publication date
EP2953597B1 (fr) 2020-03-18
US20160374863A1 (en) 2016-12-29
WO2014124242A8 (fr) 2015-03-19
WO2014124242A1 (fr) 2014-08-14
EP2953597A4 (fr) 2016-07-20

Similar Documents

Publication Publication Date Title
US7576257B2 (en) Reclosable wound dressing system
US20090287133A1 (en) Disposable or Reclosable Wound or Skin Condition Dressing and Treatment System
US11986377B2 (en) Re-closable wound dressing
US20190183695A1 (en) Surgical bandage with stabilizing elements
EP2953597B1 (fr) Pansement transparent pour plaie ou affection cutanée et système de traitement
CN202682108U (zh) 皮外伤保护隔离罩
US11992391B2 (en) Adhesive bandage
Wongkietkachorn et al. Periwound challenges improve patient satisfaction in wound care
US20200121614A1 (en) Cannabinoid-infused transparent hydrogel skin patch
JONES et al. Case study series: Lifteez aerosol and wipes for the prevention and management of MARSI.
Anderson Key principles involved in applying and removing wound dressings
CN212037937U (zh) 一种水膜疗伤贴
Williams et al. Allevyn adhesive
Hedger Choosing the most appropriate dressing: foams
CN220193343U (zh) 一种双药贴式创口贴
CN213373013U (zh) 一种带有消毒棉的创可贴
US20230240899A1 (en) Umbilical Cord Stump Protector
US20220313495A1 (en) ATRAUMATIC BANDAGE/DRESSING TO COVER WOUND, SURGICAL INCISION, EPIDERMAL MEDICAL DEVICE, or NON-MEDICAL APPLICATION
CN217339114U (zh) 一种透明创口贴
Williams Tegasorb hydrocolloid dressing: advanced formulation
US20070185427A1 (en) Adhesive bandage with reduced pain during removal
Mehaffey Skin Tears: What to Do?
Pudner Hydrocolloid dressings
TWM585595U (zh) 紗布改良結構
Pudner Vapour-Permeable Film Dressings

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150902

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160621

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 13/511 20060101ALI20160615BHEP

Ipc: A61F 13/02 20060101ALI20160615BHEP

Ipc: A61F 13/00 20060101AFI20160615BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170208

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190821

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20200122

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014062517

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1245057

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200415

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: LAGRECA, ALFRED J.

RIN2 Information on inventor provided after grant (corrected)

Inventor name: LAGRECA, ALFRED J.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200618

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602014062517

Country of ref document: DE

Owner name: LAGRECA, ALFRED J., EAST SANDWICH, US

Free format text: FORMER OWNER: LAGRECA, ALFRED J., HINGHAM, MA, US

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200619

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200618

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200812

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200718

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1245057

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200318

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014062517

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

26N No opposition filed

Effective date: 20201221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210207

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230224

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240228

Year of fee payment: 11

Ref country code: GB

Payment date: 20240222

Year of fee payment: 11